Efficacy and safety of tofacitinib in Chinese patients with active psoriatic arthritis: a phase 3, randomised, double-blind, placebo-controlled study

Efficacy and safety of tofacitinib in Chinese patients with active psoriatic arthritis: a phase 3, randomised, double-blind, placebo-controlled study

Objectives Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, were evaluated in a 6-month, double-blind, phase 3 study in Chinese patients with active (polyarthritic) psoriatic arthritis (PsA) and inadequate response to ≥1 conventional synthetic disease-modifying antirheumatic drug....

Full description

Bibliographic Details
Main Authors: Xiaofeng Zeng, Cunshan Wang, Yi Liu, Jian Xu, Ju Liu, Zhuoli Zhang, Wenfeng Tan, Shengyun Liu, Wei Lin, Weiguo Wan, Zhenyu Jiang, Zhiyi Zhang, Oluwaseyi Dina, Shixue Liu, XiaoMei Leng, Keith Kanik, Jiankang Hu, Jingyang Li, Levent M. Gunay, Cassandra Kinch
Format: Article
Language:English
Published: BMJ Publishing Group 2023-01-01
Series:RMD Open
Online Access:https://rmdopen.bmj.com/content/9/1/e002559.full

Internet

https://rmdopen.bmj.com/content/9/1/e002559.full

Similar Items